Opdivo (nivolumab)

pCPA File Number: 22796
Negotiation Status:
Active Negotiation
Indication(s):
Cabometyx in combination with nivolumab for the first-line treatment of adult patients with advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC.
Sponsor/Manufacturer:
Bristol Myers Squibb Canada Inc.
CDA-AMC Project Number:
PC0312-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable